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Abstract
Background: Although the molecular pathogenesis of pituitary adenomas has been assessed by several
different techniques, it still remains partially unclear. Ribosomal proteins (RPs) have been recently
related to human tumorigenesis, but they have not yet been evaluated in pituitary tumorigenesis.
Objective: The aim of this study was to introduce serial analysis of gene expression (SAGE), a high-
throughput method, in pituitary research in order to compare differential gene expression.
Methods: Two SAGE cDNA libraries were constructed, one using a pool of mRNA obtained from five
GH-secreting pituitary tumors and another from three normal pituitaries. Genes differentially
expressed between the libraries were further validated by real-time PCR in 22 GH-secreting pituitary
tumors and in 15 normal pituitaries.
Results: Computer-generated genomic analysis tools identified 13 722 and 14 993 exclusive genes
in normal and adenoma libraries respectively. Both shared 6497 genes, 2188 were underexpressed
and 4309 overexpressed in tumoral library. In adenoma library, 33 genes encoding RPs were
underexpressed. Among these, RPSA, RPS3, RPS14, and RPS29 were validated by real-time PCR.
Conclusion: We report the first SAGE library from normal pituitary tissue and GH-secreting pituitary
tumor, which provide quantitative assessment of cellular transcriptome. We also validated some
downregulated genes encoding RPs. Altogether, the present data suggest that the underexpression of
the studied RP genes possibly collaborates directly or indirectly with other genes to modify cell cycle
arrest, DNA repair, and apoptosis, leading to an environment that might have a putative role in the
tumorigenesis, introducing new perspectives for further studies on molecular genesis of
somatotrophinomas.
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Introduction
The molecular pathogenesis of GH-secreting pituitary
adenoma initiation and progression remains partially
unexplained. The involvement of different cyclin D1
alleles, p16 amplification, and methylation are still
obscure. Classic proto-oncogenes, such as NRAS,
MYCL1, MYCN, HRAS (HRAS1), BCL1 (CCND1),
FGF4, Sea, KRAS2 (KRAS), C-erbB-2, and FOS, and
tumor suppressors such as retinoblastoma gene (RB1)
and P53 do not appear to have a significant role in
pituitary adenoma pathogenesis (1, 2). Activating
mutations, promoter insertions, deletions, or point
mutations of PTTG (PTTG1) as well as clear correlation
between PTTG expression and mitotic index in human
pituitary tumors have not been described. It remains
unclear whether overexpression of normal PTTG has an
active role in human pituitary tumorigenesis (3).
Four genetic syndromes have provided insights into
the molecular basis of pituitary tumorigenesis. Multiple
endocrine neoplasia type 1 (MEN1), caused by germline
mutations in MEN1 (menin) or rarely in CDKN1B
(cyclin-dependent kinase (CDK) inhibitor) genes, is an
autosomal dominant condition associated with pitu-
itary adenomas in 40–60% of patients (4). In Carney
complex (CNC), unlike MEN1, only GH-secreting
adenomas have been described. In this condition, the
normal allele of the regulatory subunit type 1 of the
cAMP-dependent protein kinase A gene (PRKAR1A) is
mutated or lost (5). Pituitary adenomas of all types can
occur in a familial setting in the absence of MEN1 and
CNC – this phenotype is termed familial isolated
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pituitary adenomas (6). Germline inactivating
mutations in the AIP gene, which maps at 11q13 and
encodes the aryl hydrocarbon receptor interacting
protein, have been found in some of these families (7).
McCune–Albright syndrome, which has been associated
with GH-secreting pituitary adenomas, results from
somatic mutations in the adenylate cyclase-stimulating
G alpha protein gene (GNAS1 (GNAS)) (8). In addition,
inw40% of isolated somatotroph adenomas, activating
mutations of the GNAS1 were identified and remain
the most important pathogenic mechanism yet defined
for human pituitary adenomas (9).
New concepts in biology point out that microRNAs (10)
and ribosomal proteins (RPs) (11, 12) can act as gene
expression regulators, controlling multiple biological
processes, including cancer. RPs are core proteins that
come together with rRNA in the nucleolus to form the
small and the large subunits (40S and 60S) of the ribosome
(11). Several eukaryotic RPs have also been linked to
extra-ribosomal functions, including DNA replication,
transcription, splicing, cell growth, proliferation, apop-
tosis, and DNA repair. Recently, RP gene mutations or
altered expression were found in many human tumors
such as breast, prostate, uterine cervix, esophagus, and
liver carcinoma as well as glioblastoma (11).
Serial analysis of gene expression (SAGE) is a powerful
high-throughput genomic approach, which is based
on generating, cloning, and sequencing concatenated
short sequence tags, each representing a single
transcript derived from target tissue mRNA (13).
It has a significant advantage over microarray-based
analysis as it allows detection of the expression of
thousands of genes in a quantitative manner without
previous knowledge of their coding sequences. It has
been applied to identify a number of genes that are
over- or underexpressed in the transcriptome of different
types of cancer (14).
This study reports the first SAGE library from normal
pituitary tissue and GH-secreting pituitary tumors. We
also described and validated differentially expressed
RP genes in both tissues, which could be involved in
the pathogenesis of somatotrophinomas.
Materials and methods
Subjects
This study was approved by the Ethics Committee of
Hospital of School of Medicine of Ribeirao Preto,
University of Sao Paulo, and according to the Declara-
tion of Helsinki requirements, and written informed
consent was obtained from all participants.
Twenty-two patients (13 females, nine males; mean
age, 42G10.5 years) were diagnosed as having
acromegaly based on the failure of the GH suppression
of !1 mg/l after an oral glucose tolerance test (oGTT)
and a high insulin-like growth factor 1 (IGF1) level,
presented as the upper limit of normal range for sex-
and age-matched controls (15) (Table 1). Plasma GH
was determined by a solid-phase immunofluorometric
assay in duplicate, calibrated against the WHO 2nd
International Standard 98/574 Reference Preparation
for 22 kDa rhGH (somatropin; 1 mg/l corresponding to
3 mU/l) acquired from the National Institute for
Biological Standards and Control (NIBSC; Hertfordshire,
UK). The limit of detection for GH was 0.095 mg/l and
the intra- and interassay coefficients of variation (CV)
were 5.5 and 11.7% respectively. IGF1 was determined
in duplicate by immunoradiometric assay after
acid extraction (Diagnostic System Laboratories, Inc.,
Webster, TX, USA). The limit of detection for IGF1 was
10 mg/l, and the intra- and interassay CV were 5 and
11.3% respectively (15). All patients underwent visual
field evaluation and magnetic resonance imaging.
GH-secreting pituitary tumor samples were obtained
during transsphenoidal surgery; part of the sample was
processed for routine histopathological and immuno-
histochemical studies, and part was snap-frozen and
stored at K70 8C for molecular biology studies. All
samples were microdissected by an experienced path-
ologist in order to separate any nontumoral tissue
and disrupted using a Polytron homogenizer. Fifteen
normal pituitaries were obtained during autopsies
from subjects who had natural death without
previous evidence of any endocrine disease or
neurological abnormality.
RNA and DNA extraction
Total RNA and DNA were isolated from frozen tissues
using TRIzol reagent (Invitrogen Life Technologies,
Inc.). The quality of the RNA and DNA was evaluated
by spectrophotometry and agarose gel electrophoresis.
GNAS and AIP mutation screening
Codons 201 and 227 of the GNAS gene and the entire
AIP gene were directly sequenced. Primers and PCR
conditions to detect activating mutations of GNAS gene
(gsp oncogene) and AIP mutations in tumoral DNA were
previously described (7, 16).
SAGE library construction
Two SAGE cDNA libraries were constructed, one using a
pool of mRNA obtained from five GH-secreting pituitary
tumors and another from a pool of mRNA obtained from
three normal pituitaries. A total of 23 mg of purified
RNA from a pool of tumoral or normal samples were
used for the construction of each library using I-SAGE
kit (Invitrogen Life Technologies, Inc.). Binding mRNA
to oligo (dT) magnetic beads, cDNA synthesis and all
subsequent steps of the SAGE procedure were essentially
performed as described previously (13). After synthesis,
cDNA was digested with NlaIII as anchoring enzyme.
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The 3 0-terminal cDNA fragments were captured using
magnetic stand. SAGE cDNA tags (w10 bp attached to
the linker) were generated by binding of linkers to the
NlaIII-compatible sticky ends and then were digested
by BsmFI (site present in linkers). After blunting of the
linker-cDNA products, dimerization, and PCR amplifi-
cation (30 cycles) were performed using primers
directed against linker sequences, which were excised
by BsmFI digestion. The released ditag was purified from
the excised linkers by PAGE and bound to long
multimers of ditags (concatemers) separated by NlaIII
sites. Size separation by PAGE was performed and a
300–500 bp fraction was excised from gel, purified, and
cloned into the SphI site of pZero-1 (Invitrogen Life
Technologies, Inc.). The resulting colonies were gridded
in 96-well microtiter dishes containing Low Salt LBC
Zeocin (100 mg/ml), grown overnight at 37 8C, and
stored at 4 8C until further use. Sequencing was
performed using the DYEnamic ET Dye Terminator Kit
(GE Healthcare, Piscataway, NJ, USA) and a MegaBACE
DNA Analysis System (GE Healthcare).
The sequences were further analyzed using SAGE2000
Software (Invitrogen, Carlsbad, CA, USA) and, briefly, the
analysis steps were as follows: locate the NlaIII sites (i.e.
CATG ‘punctuation signals’) within the ditag concatemer;
extract ditags of 20–26 bases, length, which are located
between the sites; remove repeat occurrences of
ditags, including repeat occurrences in the reverse-
complemented orientation; define tags as the end-most
ten bases of each ditag, reverse-complementing the
right-handed tag; remove tags corresponding to linker
(i.e. TCCCCGTACA and TCCCTATTAA), as well as those
with unspecified bases (i.e. bases other than A, C, G, or T);
and for each tag, count its number of occurrences. The
product of this processing is a list of tags with their
corresponding count values and thus is a digital
representation of cellular gene expression (17).
Tag frequency tables were constructed from data
by the SAGE analysis software, with the minimum tag
count set at 1 and the maximum ditag length set
at 28 bp, and the parameters were set as default. The
annotation was based on the SAGEmap Data-
base (http://www.ncbi.nlm.nih.gov/SAGE). Statistical
analysis was carried out with the H2G Software
(http://gdm.fmrp.usp.br) for the comparison of two
SAGE libraries, using as reference the normal pituitary
library to evaluate over- and underexpressed genes.
RT-PCR and real-time PCR quantification
Genes differentially expressed between the libraries were
further validated by real-time PCR in 22 GH-secreting
pituitary tumors and in 15 normal pituitaries, including
those previously used in library construction. Approxi-
mately 1 mg total RNA was used in a RT reaction of
10 ml using 2.5 M oligo (dT), 5.5 mM MgCl2, 2.0 mM
dNTP, 20 U/l RNAse inhibitor, 50 U/l MultiScribe
TaqMan, and 10! RT buffer in a first-strand cDNA
synthesis kit (TaqMan RT reagents; Applied Biosystems,
Branchburg, NJ, USA). The RT-PCR cycle sequence was
Table 1 Clinical, biochemical, imaging findings, and follow-up of patients with acromegaly.
Patient Gender
Age
(years)
Tumor
diameter
(MRI; cm) IHC
IGF1
(% ULNR)
GNAS
mutation
GH
(oGTT;
ng/ml)
Remission
after
surgery
SRL
therapy
Disease
control
1 F 28 2.4 GH, PRL, FSH, LH 480 p.Q227L 10.4 No Yes Yes
2 M 29 3.0 GH, PRL 210 No 52.0 No Yes No
3 F 43 1.0 GH, PRL, LH 205 No 17.0 Yes No Yes
4 M 42 1.5 GH, PRL, LH, FSH, TSH 921 No 22.3 Yes No Yes
5 F 55 0.8 GH, PRL 680 p.R201C 1.7 Yes Yes Yes
6 M 34 1.3 GH, PRL 119 p.R201C 5.4 No Yes Yes
7 F 50 1.2 GH NA No 22.0 Yes No Yes
8 F 53 1.1 GH 232 p.R201H 3.4 No Yes Yes
9 F 30 1.9 GH 410 p.R201C 7.1 No Yes Yes
10 F 37 3.0 GH, PRL 297 No 67.0 No Yes Yes
11 M 36 1.6 GH 404 No 32.4 No Yes No
12 F 50 1.1 GH, PRL 246 p.R201C NA No Yes NAb
13 M 57 2.0 GH, PRL 758 No 28.9 No Yes No
14 M 39 2.7 GH, PRL 360 Noa 17.0 No Yes Nob
15 F 52 3.4 GH, PRL, LH 376 No 19.5 No Yes Yes
16 M 33 2.0 GH, TSH, PRL, LH 485 p.R201C 8.5 No Yes No
17 F 44 2.0 GH, PRL 835 No 1.6 No Yes No
18 F 57 1.8 GH 492 NA 1.3 No Yes Yes
19 F 54 2.8 GH 542 No 19.2 No Yes No
20 M 42 2.0 GH NA p.Q227L 104.0 Yes No Yesb
21 F 31 2.1 GH, PRL, TSH 337 No 117.0 No Yes No
22 M 26 5.8 GH, TSH, FSH, PRL NA p.R201H 338.0 No Nob NAb
F, female; M, male; IGF1, insulin-like growth factor 1; ULNR, upper limit of normal range; MRI, magnetic resonance imaging; IHC, immunohistochemistry;
PRL, prolactin; SRL, somatostatin receptor ligand; NA, not available.
aPatient presenting AIP p.R304X mutation.
bPatients without long-term follow-up.
Ribosomal proteins in somatotrophinomas 761EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012) 167
www.eje-online.org
25 8C for 10 min, 48 8C for 30 min, and 95 8C for 5 min.
Control reactions were performed to exclude genomic
DNA contamination.
RPSA, RPS3, RPS7, RPS14, and RPS29 genes were
identified among the differently expressed genes
between somatotroph adenoma and normal pituitary
libraries. cDNA of each RP gene and of GUSB, TBP,
and PGK1, used as housekeeping genes, was separately
amplified in duplicates, in a total volume of 12 ml,
in real-time PCR assays, using Applied Biosystems
7500 Real-Time PCR System (Foster City, CA, USA).
In addition, by real-time PCR, we also evaluate
SSTR2 gene expression in all samples. We used Applied
Biosystems-customized assay by-design for RPS3
(TaqMan Gene Expression Assay 79710183), RPS7
(TaqMan Gene Expression Assay 79686327),
RPS14 (TaqMan Gene Expression Assay 79685288),
RPS29 (TaqMan Gene Expression Assay 79685936),
assay on demand for RPSA (TaqMan Gene Expression
Assay Hs01080364_m1), and inventoried assay forSSTR2
(TaqMan Gene Expression Assay Hs00990356_m1). For
endogenous controls, we used PGK1 (TaqMan Gene
Expression Assay Hs99999906_m1), TBP (TaqMan Gene
Expression Assay Hs99999910_m1), and GUSB (TaqMan
Gene Expression Assay Hs99999908_m1).
Reactions were incubated in a 96-well optical plate
at 95 8C for 10 min, followed by 40 cycles of 95 8C for
15 s, and 608C for 1 min. The cycle threshold (Ct) was
defined as the fractional cycle number at which the
fluorescence surpasses the fixed threshold. The Ct data
were performed using default threshold settings.
Data were presented as the Ct of each sample of
each target gene normalized by the endogenous
controls (GUSB, TBP, and PGK1), Ct-median expression,
and calibrated by DCt-median value obtained from all
normal pituitary tissues. Each gene expression in
normal pituitary and tumoral tissue samples are
presented as mean, S.D., median, and range. Relative
quantification of gene expression was calculated using
the 2KDDCt method (18). Fold change of gene expression
observed in somatotroph adenomas compared with
normal pituitaries was determined by the median of
2KDDCt values of the former, related to median of 2KDDCt
values of the latter.
Statistical analysis
Statistical analyses were carried out using Mann–
Whitney U test for continuous variables. Fisher’s exact
test was used for categorical data such as the presence of
GNAS mutation, tumor size, remission after transsphe-
noidal surgery, control after somatostatin receptor
ligand (SRL) therapy, and the presence of exclusive GH
staining on immunohistochemistry (IHC). Data were
analyzed by GraphPad Prism 4 Software (San Diego, CA,
USA) and differences were considered significant at
P!0.05. For analysis of correlation between gene
expression of RP genes and SSTR2, the Pearson’s
correlation coefficient was used.
Results
Subjects
Table 1 shows the clinical, biochemical, and imaging
findings, and follow-up of patients with GH-secreting
pituitary tumors. Magnetic resonance imaging diag-
nosed macroadenoma in 21 out of 22 patients.
Exclusive GH staining on IHC was observed in seven
patients (31.8%), GH and prolactin (PRL) staining in
eight patients (36.4%), and GH, PRL, and glycoprotein
hormones (LH, FSH, and TSH) in seven patients
(31.8%).
Disease control was defined by GH level suppressed by
!1 ng/ml after oGTT and normal IGF1 levels for sex-
and age-matched controls. Seventeen patients (77.2%)
had no clinical or biochemical remission after trans-
sphenoidal surgery and were submitted to comp-
lementary therapy with SRL. Among these patients,
seven (41.1%) achieved control. Patient 19 achieved
disease control after SRL associated with dopamine
agonist, while patients 2, 11, 13, and 16 underwent
second surgery, radiotherapy, and treatment with
dopamine agonist.
Among 22 patients, DNA of one patient was not
available for GNAS and AIP mutation screening.
Somatic activating GNAS mutations (p.R201C,
p.R201H, and p.Q227L) were found in nine out of 21
patients (42.8%). Only one patient harbored somatic
AIP p.R304X mutation (4.7%) and it was not associated
with GNAS mutation.
SAGE analysis and selection of genes to
validation by real-time PCR
Data of SAGE libraries constructed from samples of
normal pituitary and GH-secreting pituitary tumor were
included in the Genome Data Mining Website for
normal pituitary cDNA library, http://gdm.fmrp.usp.
br/h2g/library/695 and for GH pituitary tumor cDNA
library, http://gdm.fmrp.usp.br/h2g/library/1145 of
the Molecular Genetics and Bioinformatics Laboratory
of the Department of Genetics of School of Medicine of
Ribeirao Preto, University of Sao Paulo. The libraries
analysis were performed using a web-based tool S3T
(Score System for Sequence Tags) available for free
at http://gdm.fmrp.usp.br/s3t/ (19). The analysis of
normal and adenoma libraries identified 21 030 and
22 329 unique SAGE tags respectively. Computer-
generated genomic analysis tools (http://gdm.fmrp.
usp.br) identified 13 722 exclusive genes in normal
pituitary and 14 993 in somatotroph adenoma cDNA
library. Both libraries shared 6497 genes, 2188 under-
expressed and 4309 overexpressed in tumoral library. Of
interest, PTTG gene was not expressed in tumor library
generated by the present SAGE. Differential expression
of genes related to cell adhesion, cell differentiation, cell
cycle, and apoptosis were also demonstrated between
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normal pituitary tissue and GH-secreting pituitary
tumors (Table 2).
In the normal library, SAGE also showed over-
expression of POMC (62-fold), LHb subunit (54-fold),
TSH (24-fold), PRL (fivefold), and exclusive FSHb
subunit expression compared with tumoral library. On
the other hand, GH-secreting adenoma library showed
higher expression of GH2 gene (3.2-fold).
In addition, SAGE data revealed 33 under- and 14
overexpressed RP tags in tumors. Among the under-
expressed RP genes, five of them – RPSA, RPS3, RPS7,
RPS14, and RPS29 – were selected for validation by
real-time PCR based on Ingenuity Pathway Analysis
(Ingenuity Systems, www.ingenuity.com). We observed
underexpression of RPSA (K1.4-fold; PZ0.004), RPS3
(K1.8-fold; PZ0.03), RPS14 (K1.8-fold; PZ0.001),
and RPS29 (K2.9-fold; PZ0.002). RPS7 expression
showed only a tendency to underexpression (K1.2-fold;
PZ0.08) in GH-secreting pituitary tumor compared
with normal pituitaries samples (Table 3).
We also observed no difference between SSTR2
expression by real-time PCR in GH-secreting pituitary
tumors and normal pituitaries (PZ0.4). However,
SSTR2 overexpression in tumoral samples was associ-
ated with disease control after treatment with SRL
(PZ0.01).
There was no relationship between RPSA, RPS3,
RPS14, and RPS29 expression and the presence of
GNAS mutation, IGF1 or GH levels, tumor size, exclusive
GH staining on IHC, remission after surgery, or disease
control with SRL therapy. There was no correlation
between RP gene expression and SSTR2 expression.
Discussion
This study reports the first SAGE library from normal
pituitary tissue and GH-secreting pituitary tumor. SAGE
data generated will be available at Gene Expression
Omnibus website (http://www.ncbi.nlm.nih.gov/geo/)
and will be accessed through GEO accession GSM
912557 (somatotrophinomas) and GSM912556
(normal pituitary). Our entire data will be available
at this database, providing information on differently
expressed genes in somatotroph adenomas for further
research.
Until now, most available information on the
pituitary tumor transcriptome was based on microarray
studies (20, 21). SAGE has some advantages over
microarrays because it allows detection of all expressed
sequences in a tissue, including those not previously
described (13). Similar to microarray, there is limitation
in using SAGE method in order to compare the
monoclonal somatotroph adenoma and the normal
pituitary, which contains various cell types. The fact
that normal pituitary tissue is composed of more than
50% somatotropic cells might, however, decrease
this limitation. It is also important to point out that
all high-throughput methods have exclusive advantages
and limitations. Therefore, integrating different data
sets will provide complementary knowledge on pituitary
tumorigenesis.
The molecular profile of pituitary tumor exhibited
several similarities and some differences compared with
previously published data using microarray. Genes
related to pituitary physiological hormone secretion,
such as POMC, LHb subunit, TSH, and PRLm were
differently expressed in normal tissue library. On the
other hand, GH-secreting pituitary adenoma library
showed higher expression of GH2 gene (3.2-fold).
Morris et al. (21), using microarray, also found that
GH2 as well as GH-releasing hormone receptor
(GHRHR) genes were overexpressed in GH pituitary
tumor tissue. Interestingly, PTTG gene was not
expressed in tumor library generated by the present
SAGE and, in the microarray study (21), its expression
was similar in normal pituitary and GH-secreting
tumors. These data diverge from those previously
reported by comparative RT-PCR, which demonstrated
ubiquitous and prevalent expression of PTTG in
pituitary tumors, mainly in invasive hormone-secreting
tumors (3).
In this study, differential expression of genes related
to cell adhesion, cell differentiation, cell cycle, and
apoptosis were also demonstrated between normal
pituitary tissue and GH-secreting pituitary tumors by
SAGE. These findings have not yet been validated.
However, they introduce new perspectives for further
studies on molecular genesis of somatotrophinomas.
Additional experiments and functional studies are
required to confirm these data and the involvement of
these signaling pathways in GH-secreting pituitary
tumors.
SAGE also identified 33 under- and 14 overexpressed
RP genes in the adenoma library, which might be
involved in the poorly understood pathogenesis of
GH-secreting pituitary tumors, as many extra-riboso-
mal functions in other cellular processes have been
suggested. Indeed, RP gene mutations or altered
expression have been found in many human tumors
(22, 23). In this study, based on Ingenuity Pathway
Analysis (Ingenuity Systems, www.ingenuity.com), we
chose for validation five of them – RPSA, RPS3, RPS7,
RPS14, and RPS29 – all involved in cell cycle
regulation, apoptosis, and DNA repair. We validated,
by real-time PCR, four of the five RP genes studied.
Although the role of RPs in pituitary tumorigenesis has
never been proposed, research at seed site analysis
(http://www.ncbi.nlm.nih.gov/geo/) enables us to find a
differential expression profile of all these RPs in four
pituitary adenoma subtypes (GH, PRL, ACTH-secreting
pituitary adenomas, and nonfunctioning pituitary
adenoma), reinforcing the putative role of RPs in
pituitary tumor pathogenesis (21).
RP genes have been identified in human disea-
ses, especially in genetic disorders (24). Recently,
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Table 2 Under- and overexpressed genes in GH-secreting pituitary adenoma library compared with normal pituitary library, obtained by
SAGE and involved in functional pathways. Under- and overexpressed genes described in this table refer to fold change inferior toK2.5
and superior to 2.5 respectively.
SAGE tag Unigene
Gene
symbol Gene description
Fold
change
Apoptotic pathways
GCAGGGTGGG Hs.631535 AKT2 V-akt murine thymoma viral oncogene homolog 2 K5.02
TCACTGTGGG Hs.372331 SPTAN1 Spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) K4.02
AAGCATTAAA Hs.520851 PRKAR1B Protein kinase, cAMP-dependent, regulatory, type I, beta K3.52
AAAATAAAGA Hs.73722 APEX1 APEX nuclease (multifunctional DNA repair enzyme) 1 K3.52
CCTGCCCCCC Hs.861 MAPK3 Mitogen-activated protein kinase 3 K3.01
AAAAAGCAGA Hs.443914 SOD1 Superoxide dismutase 1, soluble (amyotropic lateral sclerosis 1) K2.34
AAGCCTTGCT Hs.444356 GRB2 Growth factor receptor-bound protein 2 2.99
CTGCTGCACT Hs.271510 GSR Glutathione reductase 3.98
CCAGTGCACT Hs.220950 FOXO3 Forkhead box O3 3.98
TGAATCTGGG Hs.436687 SET SET translocation (myeloid leukemia associated) 4.98
Cell differentiation pathways
CCTAAGGCTA Hs.108371 E2F4 E2F transcription factor 4, p107/p130 binding K3.01
TATGACTTAA Hs.413812 RAC1 Ras-related C3 botulinum toxin substrate 1 K2.58
CTCTGAGGTA Hs.435714 PAK1 P21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, yeast) K2.51
TGGCTGGCCA Hs.654394 CSF1R Colony stimulating factor 1 receptor, (v-fms) oncogene
homolog
2.99
Cell adhesion pathways
AAAGGGTCAC Hs.21422 NRCAM Neuronal cell adhesion molecule K8.04
TGTGGCGTAT Hs.556600 MYLK Myosin light chain kinase K4.02
TTGCTGACTT Hs.474053 COL6A1 Collagen, type VI, alpha 1 K3.52
TGGCCTAATA Hs.1501 SDC2 Syndecan 2 K3.45
TGTTTATATT Hs.49774 PTPRM Protein tyrosine phosphatase, receptor type, M K3.01
TGAAAACTAC Hs.347270 HLA-DPA1 Major histocompatibility complex, class II, DP alpha 1 K3.01
GCATTGCTCA Hs.365689 CADM3 Cell adhesion molecule 3 K3.01
TCTTCGTCCT Hs.493919 MPZL1 Myelin protein zero-like 1 K3.01
TAATATTTTT Hs.270291 ACTN4 Actinin, alpha 4 K3.01
GTGGAGAAAA Hs.694732 ITGA4 Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4
receptor)
K3.01
CAGATTGCTG Hs.705383 PPP1CB Protein phosphatase 1, catalytic subunit, beta isoform K2.51
GACCGCAGGA Hs.17441 COL4A1 Collagen, type IV, alpha 1 2.99
CAAGAGTTTT Hs.503878 NCAM1 Neural cell adhesion molecule 1 2.99
TTTGGTTTTC Hs.489142 COL1A2 Collagen, type I, alpha 2 2.99
TCAAAAAAAA Hs.445827 COL5A2 Collagen, type V, alpha 2 3.65
TGGAAATGAC Hs.172928 COL1A1 Collagen, type I, alpha 1 4.98
CTCCAATAAA Hs.471014 TLN1 Talin 1 4.98
GGGCGGAGCT Hs.632717 MYL6 Myosin, light chain 6, alkali, smooth muscle and non-muscle 6.97
ACCCTCTTCC Hs.181244 HLA-A Major histocompatibility complex, class I, A 12.94
Cell cycle pathways
CTTAATCTTG Hs.519162 BTG2 BTG family, member 2 12.06
TGAGAGGGTG Hs.74405 YWHAQ Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein (YWHA) theta polypeptide
K6.03
GAATTAACAT Hs.513851 YWHAE (YWHA) epsilon polypeptide K4.47
AACTCCCAGT Hs.110571 GADD45B Growth arrest and DNA damage inducible, beta K4.02
AAAGTCTAGA Hs.523852 CCND1 Cyclin D1 K3.01
TAATTAAAAG Hs.40582 CDC14B CDC14 cell division cycle 14 homolog B
(Saccharomyces cerevisiae)
K3.01
CCTAAGGCTA Hs.108371 E2F4 E2F transcription factor 4, p107/p130 binding K3.01
TCAATCAAGA Hs.226755 YWHAH (YWHA) eta polypeptide K2.68
TGCATATCAT Hs.370770 XPO1 Exportin 1 (CRM1 homolog, yeast) 2.99
GCTGAAGGGG Hs.483635 FGF1 Fibroblast growth factor 1 (acidic) 2.99
CTGCACTTAC Hs.438720 MCM7 Minichromosome maintenance complex component 7 3.48
AATGTGAGTC Hs.520974 YWHAG (YWHA) gamma polypeptide 3.98
CGTCCCGGAG Hs.654838 MAD1L1 MAD1 mitotic arrest deficient-like 1 (yeast) 3.98
TCCTGCTGGC Hs.149957 RPS6KA1 Ribosomal protein S6 kinase, 90 kDa, polypeptide 1 3.98
GACAAGGTTC Hs.279562 MYT1 Myelin transcription factor 1 5.97
CCCTCCTCTC Hs.534307 CCND3 Cyclin D3 6.97
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Ebert et al. (25) provided evidence that RPS14 is a
causal gene for the 5q-syndrome. The ribosomal gene
RPS14 is required for the maturation of 40S ribosomal
subunits and maps to the deleted region in the 5q-
syndrome, suggesting that this syndrome represents a
disorder of aberrant ribosome biogenesis (26). However,
it is conceivable that other genes (on 5q or elsewhere)
collaborate with RPS14 to cause the disease phenotype.
RPS29, which is also underexpressed in our study, is
a mediator of cell death. The overexpression of RPS29
cDNA by transfection into thymocytes and HeLa cells
induce cell shrinkage, chromatin condensation, plasma
membrane alteration, nuclear fragmentation, and a
distinct internucleosomal DNA ladder, typical of
apoptosis (27). Downregulation of the expression of
apoptosis inhibitor proteins BCL2, BCL-XL, and survivin
and upregulation of pro-apoptotic p53 and Bax was
also observed, suggesting a role of RPS29 in apoptosis
modulation (28).
Besides RPS14 and RPS29, we also observed under-
expression of RPSA and RPS3 and a tendency of
underexpression of RPS7 in somatotrophinomas
compared with normal pituitaries. Mammalian cells
respond to DNA damage signals by activating cell
cycle checkpoints and DNA repair systems, or inducing
apoptosis (29). Drosophila RPS3 has been shown to
have an enzymatic activity that cleaves DNA containing
8-oxoguanine residues and an associated apurinic and
apyrimidinic (AP) lyase activity that cleaves phospho-
diester bonds (30). The AP endonuclease activity is
inseparable from activities acting upon u.v.-irradiated
DNA, which cleaves a phosphodiester bond within a
cyclobutane pyrimidine dimer. Moreover, these activities
are apparently associated with RPS3 (31). The ectopic
expression of RPS3 protein induces programmed cell
death through the activation of caspase-8 and
caspase-3, indicating that RPS3 itself is a major
determinant of cell fate (32).
Epigallocatechin-3-O-gallate (EGCG), found in green
tea, has been shown to have cancer preventive activity
in a variety of human organ sites (33). The inhibitory
effect of EGCG on tumor cell proliferation seems to be
exerted by its binding to RPSA (or 67 kDa laminin
receptor) (34, 35). In addition, RNAi-mediated silencing
of RPSA results in abrogation of EGCG-induced
apoptosis in myeloma cells by TNFa, activated Fas,
and IFNg, which are mediated by DAPK2, a key
regulatory step between the formation of death-
inducing signaling complex leading to the activation
of caspases (36) and p53 pathway (37). The induction
of p53-like proteins (p73 and p63) provides an
important alternative mechanism of cell growth arrest
in the absence of p53. These proteins are not only
involved in the induction of apoptosis genes but also
regulate genes responsible for cell cycle arrest and DNA
repair. In addition, RPSA leads to the induction of CDK
inhibitors, such as p16 and p18, which can induce cell
cycle arrest by preventing retinoblastoma phosphoryl-
ation (38). Finally, eukaryotic translation elongation
factor 1 alpha 1 (eEF1A), which is activated by RPSA
(39) and was also underexpressed in our data, is an
important component of the eukaryotic translation
apparatus and is indispensable for mediating anticancer
activity of EGCG. Therefore, the underexpression of
RPSA and eEF1A in the GH-secreting pituitary
adenomas suggest that these proteins might determine
the efficiency of cell proliferation and a decrease in
apoptosis control, probably contributing to pituitary
cancer development.
As a major negative regulator of p53, murine
MDM2 or its human analog HDM2 oncogene plays
an important role in carcinogenesis and tumor
progression. By catalyzing the ubiquitination of p53,
MDM2 promotes p53 protein degradation and, in turn,
MDM2 binds to the transcriptional activation domain
of p53 and blocks its transactivation activities (40).
Several subunit proteins of the ribosome, L5, L11, L23,
S3, and S7, bind to MDM2, thus stabilizing p53 and
rescuing its transactivational activities (41, 42, 43).
More recently, in vitro and in vivo data suggest that
Table 3 Ribosomal protein genes in GH-secreting adenoma and normal pituitary cDNA libraries evaluated by SAGE and validated by
qPCR. Frequencies A and B correspond to the number of each tag, obtained by SAGE, in normal and GH-secreting pituitary cDNA libraries,
respectively, and normalized to 300 000 total tags.
SAGE tag Unigene Gene
Frequency A
(normal
library)
Frequency B
(tumor
library)
Fold
change
(SAGE)
Normal
pituitary
(2KDDCt)
Tumor
(2KDDCt)
Fold change
(qPCR)
GAAAAATGGT Hs.449909 RPSA 963 434 K2.2 1.55G0.82;
0.78–3.26
0.88G0.44;
0.29–2.09
K1.4 (PZ0.004)
GAGAGTGGGG Hs.546286 RPS3 387 291 K1.3 1.28G0.70;
0.47–3.17
0.72G0.60;
0.17–2.81
K1.8 (PZ0.03)
TCGTCTTTAT Hs.546287 RPS7 99 19 K5.0 1.16G0.69;
0.26–2.93
0.79G0.38;
0.25–1.64
K1.2 (PZ0.08)
TAAACTGTTT Hs.381126 RPS14 114 34 K3.3 1.28G0.69;
0.59–3.10
0.73G0.52;
0.15–2.29
K1.8 (PZ0.001)
ATAATTCTTT Hs.156367 RPS29 1474 528 K2.8 1.52G0.78;
0.41–3.30
0.81G0.89;
0.09–3.78
K2.9 (PZ0.002)
The results for gene expression (2KDDCt) in normal pituitaries and in tumors are expressed as medianGS.D. and range.
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at least one biological end point of the interaction of
RPS3 with p53 and MDM2 is to protect p53 from
MDM2-mediated ubiquitination (44, 45). In addition,
RPS7, another protein of the small subunit of the
ribosome, has the capacity to stabilize p53 by binding
to MDM2 (42). Therefore, the underexpression of RPS3
and RPS7, which act as a scaffold for the additional
binding of MDM2 and p53, would affect the genomic
integrity facilitating GH-secreting pituitary adenoma
development. Indeed, the RPS3 is located at 11q13.3–
q13.5, a locus where AIP, a pituitary adenoma
susceptibility gene, has been identified. Germline
mutations in AIP cause a low-penetrance pituitary
adenoma predisposition, with particularly high relative
risk of GH-secreting pituitary adenomas. As AIP
identification, a number of single-exon and partial/
whole-gene deletions detected in several tumor sup-
pressor genes have been reported to cause hereditary
tumor susceptibility (7). AIP as well as MEN1 gene
are located from 61 897K to 64 592K, and RPS3
is closely located at 72 424K on 11q.13; therefore,
the underexpression of RPS3 gene could modulate AIP
and/or MEN1 genes or similar to them might act as a
tumor suppressor gene.
In conclusion, we report the first SAGE libraries from
normal pituitary tissue and GH-secreting pituitary
tumor, which provide a quantitative assessment of the
cellular transcriptome. Differential expression of genes
related to cell adhesion, cell differentiation, cell cycle,
and apoptosis were demonstrated by SAGE, introducing
new perspectives for further studies. We validated
some underexpressed genes that encode RPs. The data
observed in this sample suggest that the underexpres-
sion of the studied RP genes possibly collaborates
directly or indirectly with other genes, as summarized
in Fig. 1, to modify cell cycle arrest, DNA repair, and
apoptosis, leading to an environment that might have a
putative role in the somatotrophinoma tumorigenesis.
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